Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT06132958




Registration number
NCT06132958
Ethics application status
Date submitted
10/11/2023
Date registered
15/11/2023
Date last updated
10/06/2024

Titles & IDs
Public title
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
Scientific title
A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy (MK-2870-005/ENGOT-en23/GOG-3095)
Secondary ID [1] 0 0
2023-504816-14
Secondary ID [2] 0 0
2870-005
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Endometrial Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Womb (Uterine or endometrial cancer)

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - Sacituzumab tirumotecan
Treatment: Drugs - Doxorubicin
Treatment: Drugs - Paclitaxel

Experimental: Sacituzumab tirumotecan - Participants will receive 4 mg/kg of sacituzumab tirumotecan via intravenous (IV) infusion on Day 1 of each 14-day cycle. Additionally, participants receive diphenhydramine (or equivalent), a Histamine (H2 antagonist) of investigator's choice, acetaminophen (or equivalent), and dexamethasone (or equivalent) per each drug's product label prior to the first 4 infusions of sacituzumab tirumotecan. At subsequent infusions, the H2 antagonist and dexamethasone are optional, at the discretion of the investigator.

Active Comparator: Chemotherapy - Participants will receive 60 mg/m^2 of doxorubicin by IV infusion on Day 1 of each 21-day cycle; or 80 mg/m^2 of paclitaxel by IV infusion on Days 1, 8, and 15 of each 28-day cycle.


Other interventions: Sacituzumab tirumotecan
4 mg/kg of sacituzumab tirumotecan by IV infusion

Treatment: Drugs: Doxorubicin
60 mg/m^2 of doxorubicin by IV Infusion

Treatment: Drugs: Paclitaxel
80 mg/m^2 of paclitaxel by IV infusion
Intervention code [1] 0 0
Other interventions
Intervention code [2] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR)
Timepoint [1] 0 0
Up to approximately 4 years
Primary outcome [2] 0 0
Overall Survival (OS)
Timepoint [2] 0 0
Up to approximately 4 years
Secondary outcome [1] 0 0
Objective Response Rate (ORR) per RECIST 1.1 as Assessed by BICR
Timepoint [1] 0 0
Up to approximately 4 years
Secondary outcome [2] 0 0
Duration of Response (DOR) per RECIST 1.1 as Assessed by BICR
Timepoint [2] 0 0
Up to approximately 4 years
Secondary outcome [3] 0 0
Number of Participants Who Experience One or More Adverse Events (AEs)
Timepoint [3] 0 0
Up to approximately 4 years
Secondary outcome [4] 0 0
Number of Participants Who Discontinue Study Intervention Due to an AE
Timepoint [4] 0 0
Up to approximately 4 years
Secondary outcome [5] 0 0
Change from Baseline in Global Health Status/Quality of Life Score (European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30 [EORTC QLQ-C30])
Timepoint [5] 0 0
Baseline, up to approximately 4 years

Eligibility
Key inclusion criteria
The main inclusion and exclusion criteria include but are not limited to the following:



- Has a histologically-confirmed diagnosis of endometrial carcinoma or carcinosarcoma.

- Has radiographically evaluable disease, either measurable or nonmeasurable per
response evaluation criteria in solid tumors (RECIST 1.1), as assessed by blinded
independent central review (BICR).

- Has received prior platinum-based chemotherapy and anti-programmed cell death 1
protein (PD-1)/anti- programmed cell death ligand 1 (PD-L1) therapy, either separately
or in combination.
Minimum age
18 Years
Maximum age
No limit
Sex
Females
Can healthy volunteers participate?
No
Key exclusion criteria
- Has neuroendocrine tumors or endometrial sarcoma, including stromal sarcoma,
leiomyosarcoma, adenosarcoma, or other types of pure sarcomas.

- Has a history of documented severe dry eye syndrome, severe Meibomian gland disease
and/or blepharitis, or corneal disease that prevents/delays corneal healing.

- Has active inflammatory bowel disease requiring immunosuppressive medication or
previous history of inflammatory bowel disease.

- Has had a recurrence of endometrial carcinoma or carcinosarcoma more than 180 days
after completing platinum-based therapy administered in the curative-intent or
adjuvant setting without any additional platinum-based therapy received in the
metastatic or recurrent setting.

- Has received more than 3 prior lines of therapy for endometrial carcinoma or
carcinosarcoma.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
6/12/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
10/01/2028
Actual
Sample size
Target
710
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment hospital [1] 0 0
Blacktown Hospital ( Site 1101) - Blacktown
Recruitment hospital [2] 0 0
GenesisCare North Shore ( Site 1103) - St Leonards
Recruitment hospital [3] 0 0
Royal Brisbane and Women's Hospital ( Site 1102) - Brisbane
Recruitment hospital [4] 0 0
Epworth Freemasons ( Site 1104) - East Melbourne
Recruitment hospital [5] 0 0
Frankston Hospital ( Site 1105) - Frankston
Recruitment postcode(s) [1] 0 0
2148 - Blacktown
Recruitment postcode(s) [2] 0 0
2065 - St Leonards
Recruitment postcode(s) [3] 0 0
4029 - Brisbane
Recruitment postcode(s) [4] 0 0
3002 - East Melbourne
Recruitment postcode(s) [5] 0 0
3199 - Frankston
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Connecticut
Country [3] 0 0
United States of America
State/province [3] 0 0
District of Columbia
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Indiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Louisiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Missouri
Country [10] 0 0
United States of America
State/province [10] 0 0
Nevada
Country [11] 0 0
United States of America
State/province [11] 0 0
New York
Country [12] 0 0
United States of America
State/province [12] 0 0
North Carolina
Country [13] 0 0
United States of America
State/province [13] 0 0
Ohio
Country [14] 0 0
United States of America
State/province [14] 0 0
Tennessee
Country [15] 0 0
United States of America
State/province [15] 0 0
Texas
Country [16] 0 0
Argentina
State/province [16] 0 0
Buenos Aires
Country [17] 0 0
Argentina
State/province [17] 0 0
Caba
Country [18] 0 0
Argentina
State/province [18] 0 0
La Rioja
Country [19] 0 0
Austria
State/province [19] 0 0
Tirol
Country [20] 0 0
Belgium
State/province [20] 0 0
Oost-Vlaanderen
Country [21] 0 0
Belgium
State/province [21] 0 0
Vlaams-Brabant
Country [22] 0 0
Belgium
State/province [22] 0 0
West-Vlaanderen
Country [23] 0 0
Belgium
State/province [23] 0 0
Namur
Country [24] 0 0
Brazil
State/province [24] 0 0
Santa Catarina
Country [25] 0 0
Canada
State/province [25] 0 0
Quebec
Country [26] 0 0
Chile
State/province [26] 0 0
Araucania
Country [27] 0 0
Chile
State/province [27] 0 0
Region M. De Santiago
Country [28] 0 0
Czechia
State/province [28] 0 0
Moravskoslezsky Kraj
Country [29] 0 0
Czechia
State/province [29] 0 0
Novy Jicin
Country [30] 0 0
Czechia
State/province [30] 0 0
Olomoucky Kraj
Country [31] 0 0
Czechia
State/province [31] 0 0
Praha 8
Country [32] 0 0
Denmark
State/province [32] 0 0
Hovedstaden
Country [33] 0 0
Denmark
State/province [33] 0 0
Midtjylland
Country [34] 0 0
Finland
State/province [34] 0 0
Pirkanmaa
Country [35] 0 0
Finland
State/province [35] 0 0
Pohjois-Savo
Country [36] 0 0
Finland
State/province [36] 0 0
Uusimaa
Country [37] 0 0
Finland
State/province [37] 0 0
Varsinais-Suomi
Country [38] 0 0
France
State/province [38] 0 0
Centre
Country [39] 0 0
France
State/province [39] 0 0
Cotes-d Armor
Country [40] 0 0
France
State/province [40] 0 0
Doubs
Country [41] 0 0
France
State/province [41] 0 0
Herault
Country [42] 0 0
France
State/province [42] 0 0
Ille-et-Vilaine
Country [43] 0 0
France
State/province [43] 0 0
Nord-Pas-de-Calais
Country [44] 0 0
France
State/province [44] 0 0
Rhone-Alpes
Country [45] 0 0
France
State/province [45] 0 0
Paris
Country [46] 0 0
Greece
State/province [46] 0 0
Attiki
Country [47] 0 0
Israel
State/province [47] 0 0
Haifa
Country [48] 0 0
Israel
State/province [48] 0 0
Holon
Country [49] 0 0
Israel
State/province [49] 0 0
Jerusalem
Country [50] 0 0
Israel
State/province [50] 0 0
Petah Tikva
Country [51] 0 0
Israel
State/province [51] 0 0
Ramat Gan
Country [52] 0 0
Israel
State/province [52] 0 0
Tel Aviv
Country [53] 0 0
Italy
State/province [53] 0 0
Lazio
Country [54] 0 0
Italy
State/province [54] 0 0
Milano
Country [55] 0 0
Italy
State/province [55] 0 0
Brescia
Country [56] 0 0
Italy
State/province [56] 0 0
Napoli
Country [57] 0 0
Italy
State/province [57] 0 0
Torino
Country [58] 0 0
Japan
State/province [58] 0 0
Saitama
Country [59] 0 0
Korea, Republic of
State/province [59] 0 0
Kyonggi-do
Country [60] 0 0
Korea, Republic of
State/province [60] 0 0
Seoul
Country [61] 0 0
Malaysia
State/province [61] 0 0
Kuala Lumpur
Country [62] 0 0
Netherlands
State/province [62] 0 0
Zuid-Holland
Country [63] 0 0
Norway
State/province [63] 0 0
Rogaland
Country [64] 0 0
Norway
State/province [64] 0 0
Troms
Country [65] 0 0
Norway
State/province [65] 0 0
Vest-Agder
Country [66] 0 0
Norway
State/province [66] 0 0
Oslo
Country [67] 0 0
Poland
State/province [67] 0 0
Mazowieckie
Country [68] 0 0
Poland
State/province [68] 0 0
Podlaskie
Country [69] 0 0
Poland
State/province [69] 0 0
Wielkopolskie
Country [70] 0 0
Puerto Rico
State/province [70] 0 0
Ponce
Country [71] 0 0
Puerto Rico
State/province [71] 0 0
San Juan
Country [72] 0 0
Singapore
State/province [72] 0 0
Central Singapore
Country [73] 0 0
Spain
State/province [73] 0 0
Andalucia
Country [74] 0 0
Spain
State/province [74] 0 0
Barcelona
Country [75] 0 0
Spain
State/province [75] 0 0
Madrid, Comunidad De
Country [76] 0 0
Spain
State/province [76] 0 0
Valenciana, Comunitat
Country [77] 0 0
Sweden
State/province [77] 0 0
Skane Lan
Country [78] 0 0
Sweden
State/province [78] 0 0
Stockholms Lan
Country [79] 0 0
Switzerland
State/province [79] 0 0
Grisons
Country [80] 0 0
Switzerland
State/province [80] 0 0
Ticino
Country [81] 0 0
Switzerland
State/province [81] 0 0
Berne
Country [82] 0 0
United Kingdom
State/province [82] 0 0
England
Country [83] 0 0
United Kingdom
State/province [83] 0 0
London, City Of
Country [84] 0 0
United Kingdom
State/province [84] 0 0
Sutton
Country [85] 0 0
United Kingdom
State/province [85] 0 0
Manchester

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Merck Sharp & Dohme LLC
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
European Network for Gynaecological Oncological Trial groups(ENGOT)
Address [1] 0 0
Country [1] 0 0
Other collaborator category [2] 0 0
Other
Name [2] 0 0
GOG Foundation
Address [2] 0 0
Country [2] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The primary objectives of this study are to compare sacituzumab tirumotecan to Treatment of
Physician's Choice (TPC) with respect to progression-free survival (PFS) per response
evaluation criteria in solid tumors (RECIST 1.1), as assessed by blinded independent central
review (BICR), and overall survival (OS). The primary hypotheses are that sacituzumab
tirumotecan is superior to TPC with respect to PFS per RECIST 1.1, as assessed by BICR, and
that sacituzumab tirumotecan is superior to TPC with respect to OS.
Trial website
https://clinicaltrials.gov/ct2/show/NCT06132958
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Medical Director
Address 0 0
Merck Sharp & Dohme LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Toll Free Number
Address 0 0
Country 0 0
Phone 0 0
1-888-577-8839
Fax 0 0
Email 0 0
Trialsites@merck.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT06132958